MK-1775: ATP-Competitive Wee1 Kinase Inhibitor for G2 Checkpoint Abrogation in Cancer Research

Executive Summary: MK-1775, provided by APExBIO (SKU: A5755), is a highly selective ATP-competitive inhibitor of Wee1 kinase with an IC₅₀ of 5.2 nM in cell-free kinase assays. It abrogates the G2 DNA damage checkpoint by preventing CDC2 phosphorylation at Tyr15, sensitizing p53-deficient tumor cells to DNA-damaging agents such as gemcitabine and cisplatin (Schwartz 2022). MK-1775 demonstrates >100-fold selectivity over Myt1 kinase and is effective in vitro at nanomolar concentrations. The compound is DMSO-soluble (>25 mg/mL), stable as a solid at -20°C, and widely applied in cancer biology research workflows. Its functional specificity and robust evidence base make it a cornerstone for cell cycle checkpoint abrogation and chemosensitization studies (APExBIO product page).

Biological Rationale

Wee1 is a nuclear serine/threonine kinase that negatively regulates entry into mitosis by phosphorylating CDC2 (CDK1) at tyrosine 15. This phosphorylation maintains the G2 DNA damage checkpoint, allowing DNA repair before cell division. In many cancers, especially those with p53 mutations, the G1 checkpoint is compromised, increasing reliance on the G2 checkpoint for survival following DNA damage (Schwartz 2022). Inhibition of Wee1 disrupts this checkpoint, forcing premature mitotic entry and increasing cell death when combined with DNA-damaging agents. This rationale underpins the use of MK-1775 (Wee1 kinase inhibitor) as a research tool for studying cell cycle dynamics, DNA repair, and chemosensitization in oncology models.

Mechanism of Action of MK-1775 (Wee1 kinase inhibitor)

MK-1775 is an ATP-competitive inhibitor targeting the catalytic site of Wee1 kinase. It exhibits an IC₅₀ of 5.2 nM in cell-free kinase assays, indicating high potency (APExBIO). By binding to Wee1, MK-1775 prevents phosphorylation of CDC2 at Tyr15. This results in unchecked activation of CDC2/cyclin B complex, collapse of the G2 DNA damage checkpoint, and forced cell cycle progression. The effect is most pronounced in p53-deficient tumor cells, which lack a functional G1 checkpoint and are thus highly dependent on G2 arrest for DNA repair and survival (Schwartz 2022). MK-1775 displays >100-fold selectivity for Wee1 over Myt1 kinase and demonstrates minimal off-target activity in kinase panels at relevant concentrations, supporting its utility in mechanistic cell cycle research.

Evidence & Benchmarks

• MK-1775 inhibits Wee1 kinase activity with an IC₅₀ of 5.2 nM in cell-free kinase assays at 25°C, pH 7.4 (APExBIO).
• MK-1775 prevents CDC2 phosphorylation at Tyr15, abrogating the G2 DNA damage checkpoint in p53-mutant cell lines (Schwartz 2022).
• MK-1775 sensitizes p53-deficient cancer cells to DNA-damaging agents (gemcitabine, cisplatin, carboplatin), enhancing cell death compared to drug alone (Schwartz 2022).
• MK-1775 demonstrates >100-fold selectivity for Wee1 over Myt1 kinase in comparative enzymatic assays (APExBIO).
• Stock solutions in DMSO (>25 mg/mL) are stable for several months at -20°C, but aqueous solutions degrade rapidly (APExBIO).
• Relative and fractional viability assays delineate MK-1775's effects on proliferation versus cell death in vitro, with nanomolar EC₅₀ values for checkpoint abrogation (Schwartz 2022, Table 3.2).

This article extends and updates prior coverage in "MK-1775: ATP-Competitive Wee1 Kinhibitor for Precision G2..." by providing new benchmarks and clarifying storage and selectivity data. For a comparative analysis of protocol nuances, see "MK-1775: Expanding the Frontier of Wee1 Kinase Inhibition...", which this article complements by emphasizing evidence-based selectivity and workflow integration.

Applications, Limits & Misconceptions

Primary Applications:

• Abrogation of the G2 DNA damage checkpoint in p53-deficient cancer cell lines.
• Chemosensitization of tumor cells to DNA-damaging agents (e.g., gemcitabine, cisplatin, carboplatin).
• Mechanistic studies of cell cycle regulation and checkpoint fidelity.
• In vitro evaluation of DNA damage response inhibitors and cell viability metrics (Schwartz 2022).

Limits & Misconceptions:

Common Pitfalls or Misconceptions

• MK-1775 is not broadly cytotoxic: It shows moderate antiproliferative effects at higher concentrations; primary activity is checkpoint abrogation, not direct cytotoxicity.
• Not a substitute for G1 checkpoint inhibitors: Efficacy depends on p53 status; minimal effect in p53-wildtype cells due to intact G1 checkpoint.
• Not suitable for aqueous storage: The compound is insoluble in water and ethanol; only DMSO stock solutions are recommended.
• Does not replace DNA-damaging agents: MK-1775 is a sensitizer, not a primary cytotoxic agent; optimal results occur in combination regimens.
• In vivo pharmacokinetics may differ: This dossier covers in vitro research applications; in vivo dosing, metabolism, and toxicity may not be directly extrapolated.

Workflow Integration & Parameters

MK-1775 (A5755) from APExBIO is supplied as a solid for research use. Recommended storage is at -20°C, protected from light and moisture. For in vitro applications, dissolve in DMSO at concentrations up to 25 mg/mL. Stock solutions remain stable for several months at -20°C but degrade rapidly in aqueous or ambient conditions (APExBIO). Typical working concentrations in cell-based assays range from 10 nM to 1 μM, with efficacy dependent on cell line, p53 status, and co-administered agents. Optimal results are observed when combined with DNA-damaging agents in p53-deficient backgrounds. For advanced workflow design and troubleshooting, see "Redefining Cell Cycle Checkpoint Abrogation...", which this dossier updates with additional selectivity and storage guidance.

Conclusion & Outlook

MK-1775 is a validated, highly selective ATP-competitive Wee1 kinase inhibitor with robust evidence for G2 checkpoint abrogation and chemosensitization in p53-deficient cancer models. Its specificity, storage stability, and compatibility with standard in vitro assays make it a foundational tool for cancer biology and DNA damage response research. Future directions include in vivo validation, resistance mechanism studies, and expanding combinatorial regimens with emerging DNA repair inhibitors (Schwartz 2022).

For ordering and technical specifications, see the MK-1775 (Wee1 kinase inhibitor) product page.